[{"NetIncomeLoss_1_Q2_USD":-16549000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":4904000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":36670353.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":38441729.0,"CommitmentsAndContingencies_0_Q2_USD":null,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-123000.0,"AssetsCurrent_0_Q2_USD":221350000.0,"DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_2_Q2_pure":1.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":33573618.0,"GeneralAndAdministrativeExpense_2_Q2_USD":9491000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":841000.0,"Assets_0_Q2_USD":228516000.0,"ShareBasedCompensation_2_Q2_USD":4371000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":3715000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":347000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":523000.0,"CommonStockSharesAuthorized_0_Q2_shares":150000000.0,"CommonStockSharesIssued_0_Q2_shares":39830767.0,"DepreciationAndAmortization_2_Q2_USD":31000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"OperatingLeaseLiability_0_Q2_USD":4215000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":12388000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":4562000.0,"CommonStockValue_0_Q2_USD":40000.0,"OtherNonoperatingIncome_2_Q2_USD":1227000.0,"OtherNonoperatingIncome_1_Q2_USD":623000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-85000.0,"CostsAndExpenses_2_Q2_USD":30092000.0,"CostsAndExpenses_1_Q2_USD":17292000.0,"FinancialLiabilitiesFairValueDisclosure_0_Q2_USD":0.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-28277000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-16549000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-28277000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-16549000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":1260000.0,"OtherAssetsNoncurrent_0_Q2_USD":1970000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":218105000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":2031000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":354341000.0,"Liabilities_0_Q2_USD":15712000.0,"OperatingIncomeLoss_2_Q2_USD":-30092000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":20601000.0,"OperatingIncomeLoss_1_Q2_USD":-17292000.0,"InvestmentIncomeInterest_1_Q2_USD":120000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":2497000.0,"LiabilitiesCurrent_0_Q2_USD":13681000.0,"AccountsPayableCurrent_0_Q2_USD":1992000.0,"NonoperatingIncomeExpense_2_Q2_USD":1815000.0,"NonoperatingIncomeExpense_1_Q2_USD":743000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":219360000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":3245000.0,"DefinedContributionPlanEmployerDiscretionaryContributionAmount_2_Q2_USD":200000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-23877000.0,"DefinedContributionPlanEmployerDiscretionaryContributionAmount_1_Q2_USD":100000.0,"SubleaseIncome_2_Q2_USD":1227000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":1970000.0,"StockIssued1_2_Q2_USD":2043000.0,"LesseeOperatingLeaseDiscountRate_0_Q2_pure":0.095,"OperatingLeasePayments_2_Q2_USD":1604000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":226000.0,"NetIncomeLoss_2_Q2_USD":-28277000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":1093000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":2590000.0,"RestrictedCashNoncurrent_0_Q2_USD":1255000.0,"CommonStockSharesOutstanding_0_Q2_shares":39830767.0,"ConvertiblePreferredStockConvertedToOtherSecurities_2_Q2_USD":25481000.0,"PreferredStockValue_0_Q2_USD":null,"OperatingLeaseCost_2_Q2_USD":1200000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":228516000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":1262000.0,"PreferredStockSharesAuthorized_0_Q2_shares":9000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":4371000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":2590000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":2184000.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":1666000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.77,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.43,"ProfitLoss_2_Q2_USD":-28277000.0,"StockholdersEquity_0_Q2_USD":212804000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":123000.0,"VariableLeaseCost_2_Q2_USD":403000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-226977000.0,"LeaseCost_2_Q2_USD":376000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-24085000.0,"InvestmentIncomeInterest_2_Q2_USD":245000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":1224000.0,"Ticker":"COGT","CIK":"1622229","name":"COGENT BIOSCIENCES, INC.","OfficialName":"Cogent Biosciences Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"369716293.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210816"}]